Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTMT1 | Q9BV86 | 16/20 | 0.45 |
| ▸ | UGCG | Q16739 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193279 | 0.91 | KDM4E (0.50) | NTMT1UGCGNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3208629 | 0.84 | MAPT (0.48) | NTMT1UGCGMAPTRAB9A | |
| SCHEMBL21774206 | 0.80 | KDM4E (0.45) | NTMT1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL13404675 | 0.77 | NPC1 (0.53) | NTMT1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3205684 | 0.76 | NPC1 (0.52) | NTMT1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL12614687 | 0.76 | NTMT1 (0.58) | NTMT1UGCGNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13404712 | 0.75 | HRH3 (0.51) | NTMT1UGCG | |
| SCHEMBL3209822 | 0.75 | HRH3 (0.51) | NTMT1UGCG | |
| SCHEMBL3554861 | 0.74 | SMN1; SMN2 (0.48) | NTMT1UGCGNPC1MAPTRAB9A | |
| SCHEMBL13680487 | 0.73 | ALDH1A1 (0.49) | NPC1MAPTRAB9ASMN1; SMN2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705025-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090048225-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048225-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | NTMT1 1575/4885UGCG 2413/4885NPC1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.